The New Valeant Model
This article was originally published in RPM Report
This sounds like a winning formula for the biopharma industry in the current climate: voluntarily adopt greater transparency, increase R&D spending and promise restraint on pricing. But is Valeant really the right company to lead the way?
You may also be interested in...
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.